Global Prostacyclin Market, By Diseases (Pulmonary Arterial Hypertension, Others), Drugs (Epoprostenol, Treprostinil, Iloprost, Others), Drug Type (Generic, Branded), Dosage (Oral, Parenteral, Inhalations, Others), End-Users (Hospitals, Specialty Clinics, Home Healthcare, Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Market Analysis and Insights: Global Prostacyclin Market
Global prostacyclin market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a healthy CAGR in the above-mentioned research forecast period. Emerging markets and huge investments in research and development are the factors responsible for the growth of this market.
However, the increased prevalence of pulmonary arterial hypertension, a robust drug pipeline, and changing lifestyle, drives the global prostacyclin market. Moreover, technological advancement in treatment & diagnosis and the growing geriatric population also boost up the market growth. But, the high cost of the drug and adverse effects related to the treatment may hamper the global prostacyclin market.
Prostacyclin is a member of the endogenous prostanoid family, which is produced from the arachidonic acid, through the action of prostacyclin synthase and cyclooxygenase. Prostacyclin is a very potent endogenous inhibitor of platelet aggregation as well as a strong vasodilator that also inhibits the growth of vascular smooth muscle cells.
Prostacyclin drugs are very expensive and it is estimated that the annual costs of prostacyclin was found to be USD 30,000 to more than USD 200,000 per patient per year in the United States.
This prostacyclin market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Global Prostacyclin Market Scope and Market Size
The prostacyclin market is segmented on the basis of disease, drugs, drug type, dosage, end-users and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of disease, the prostacyclin market is segmented into pulmonary arterial hypertension and others.
- On the basis of drugs, the prostacyclin market is segmented into epoprostenol, treprostinil, iloprost and others.
- On the basis of drug type, the prostacyclin market is segmented into generics and branded. Branded segment further divided into flolan, Remodulin, Tyvaso, orenitram, ventavis and others.
- On the basis of dosage, the prostacyclin market is segmented into oral, parenteral, inhalations and others.
- On the basis of end-users, the prostacyclin market is segmented into hospitals, specialty clinics and others.
- On the basis of distribution channel, the prostacyclin market has also been segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy and others.
Prostacyclin Market Country Level Analysis
Prostacyclin market is analysed and market size information is provided by country, disease, drugs, drug type, dosage, end-users and distribution channel as referenced above.
The countries covered in the prostacyclin market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.
On geographical estimation, North America accounts the largest market share due to the increased consumption of prostacyclin for the treatment of pulmonary arterial hypertension. Europe accounts the second largest market share due to increased respiratory diseases and presence of refined medical facilities. Asia-Pacific is expected to account for the largest market share over coming years for the prostacyclin market due to increased advancement in the technology as well as growing healthcare expenditure.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Prostacyclin market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Prostacyclin Market Share Analysis
Prostacyclin market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to prostacyclin market.
The major players covered in the prostacyclin market are GlaxoSmithKline PLC., Teva Pharmaceuticals Industries Ltd., Actelion Pharmaceuticals US, Inc., United Therapeutics Corp., Sandoz AG, Dr. Reddy's Laboratories Ltd, and Par Pharmaceutical among other domestic and global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-